biostudies-literatureUnknown40(1)Ambroz MHorizon 2020 Framework ProgrammeEuropean CommissionH2020 Marie Skłodowska-Curie Actions<h4>Background</h4>Sex differences in clinical outcomes have been observed for patients with type 2 diabetes mellitus (T2DM). These could be related to sex disparities in treatment.<h4>Objectives</h4>To determine whether there are sex disparities in medication prescribing amongst patients with T2DM.<h4>Methods</h4>A cohort study was conducted using the Groningen Initiative to ANalyze Type 2 diabetes Treatment (GIANTT) database, which includes data from primary care patients with T2DM from the north of the Netherlands. Data on demographics, physical examinations, laboratory measurements and prescribing were extracted. A set of validated prescribing quality indicators assessing the prevalence, start, intensification and safety of glucose-, lipid-, blood pressure- and albuminuria-lowering medDiabetic medicine : a journal of the British Diabetic Associatione14987https://www.ebi.ac.uk/biostudies/studies/S-EPMC10098565biostudies-literatureSex disparities in medication prescribing amongst patients with type 2 diabetes mellitus managed in primary care.PMC10098565Geelink MSmits KPJDenig Pde Vries STAmbroz MfalseSex disparities in medication prescribing amongst patients with type 2 diabetes mellitus managed in primary care.<h4>Background</h4>Sex differences in clinical outcomes have been observed for patients with type 2 diabetes mellitus (T2DM). These could be related to sex disparities in treatment.<h4>Objectives</h4>To determine whether there are sex disparities in medication prescribing amongst patients with T2DM.<h4>Methods</h4>A cohort study was conducted using the Groningen Initiative to ANalyze Type 2 diabetes Treatment (GIANTT) database, which includes data from primary care patients with T2DM from the north of the Netherlands. Data on demographics, physical examinations, laboratory measurements and prescribing were extracted. A set of validated prescribing quality indicators assessing the prevalence, start, intensification and safety of glucose-, lipid-, blood pressure- and albuminuria-lowering med2023-01-01T00:00:00Z2023 Jan2025-04-18T21:20:15.13Z2025-02-18T23:40:14.711ZS-EPMC100985653627889210.1111/dme.14987